TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Increase in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 46,900 shares, an increase of 47.5% from the November 15th total of 31,800 shares. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is currently 1.1 days. Currently, 1.7% of the company’s stock are short sold.

TriSalus Life Sciences Trading Down 0.5 %

NASDAQ:TLSI traded down $0.02 during mid-day trading on Friday, hitting $3.95. 16,355 shares of the company’s stock were exchanged, compared to its average volume of 39,713. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The company has a 50 day simple moving average of $4.20 and a 200-day simple moving average of $5.09. The firm has a market capitalization of $120.44 million, a P/E ratio of -1.59 and a beta of 0.56.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently modified their holdings of the stock. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences in the second quarter worth $1,184,000. Duquesne Family Office LLC lifted its position in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the period. Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences in the second quarter worth about $240,000. Finally, MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the 3rd quarter worth $184,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TLSI has been the subject of several research analyst reports. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective for the company. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target for the company. Northland Securities started coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Canaccord Genuity Group lowered their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.08.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.